Evidence map›Paper›PMID 29777341›Full record

ReviewRheumatology international2018

Improvement of neurological and ocular symptoms of Behçet's disease after the introduction of infliximab.

Marko Barešić, Mirna Reihl, Mario Habek, Nenad Vukojević, Branimir Anić

Abstract readCase ReportsReview
PubMed Publisher
In one paragraph

Review in Rheumatology international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Observational
  4. Article
  5. [Progress in interferon: A treatment of Behcet syndrome].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2020
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Marko BarešićDivision of Clinical Immunology and Rheumatology, Department of Internal Medicine, School of Medicine, University of Zagreb, University Hospital Center Zagreb, Kišpatićeva 12, 10000, Zagreb, Croatia.ORCID http://orcid.org/0000-0001-6281-5705
Mirna ReihlDivision of Physical Medicine, Rehabilitation and Rheumatology, Vukovar General Hospital, Županijska 35, 32000, Vukovar, Croatia. mirna.reihl@gmail.com.ORCID http://orcid.org/0000-0003-3074-1646
Mario HabekDepartment of Neurology, Referral Center for Autonomic Nervous System Disorders, School of Medicine, University of Zagreb, University Hospital Center Zagreb, Kišpatićeva 12, 10000, Zagreb, Croatia.ORCID http://orcid.org/0000-0002-3360-1748
Nenad VukojevićDepartment of Ophthalmology, School of Medicine, University of Zagreb, University Hospital Centre Zagreb, Kišpatićeva 12, 10000, Zagreb, Croatia.ORCID http://orcid.org/0000-0001-7561-8858
Branimir AnićDivision of Clinical Immunology and Rheumatology, Department of Internal Medicine, School of Medicine, University of Zagreb, University Hospital Center Zagreb, Kišpatićeva 12, 10000, Zagreb, Croatia.
University Hospital Centre Zagreb · HRPolytechnic Lavoslav Ružička Vukovar · HR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Behçet's disease is a chronic inflammatory condition of unknown origin characterized by multiple organ involvement. The most common symptoms of Behçet's disease are recurrent oral and/or genital ulcerations in combination with symptoms affecting eyes, skin, central and peripheral nervous system, blood vessels and gastrointestinal tract. We present a 43-year-old female patient with the history of recurrent episodes of genital and oral ulcerations, elevated acute phase reactants and skin lesions. The diagnosis of Behçet's disease has been delayed (for more than 10 years) and reached only after she developed neurological and ocular symptoms. Treatment with glucocorticoids and azathioprine was partially successful. High doses of glucocorticoids were needed to control the disease and cyclosporine A was nephrotoxic. Remission was reached after the introduction of infliximab (plus methotrexate) and glucocorticoids were stopped. In the recent years, infliximab has been accepted as a standard therapy for refractory cases of Behçet's disease (neurological, ocular or gastrointestinal). Our patient presented with refractory ocular and neurological symptoms and infliximab was effective for both manifestations. Long-term side-effects of glucocorticoids and other immunosuppressants can be avoided with TNF-α blockade. We emphasize the importance of a timely and accurate diagnosis and significance of excluding more common diseases in a work-up algorithm.

Indexed as

AdultAntibodies, MonoclonalBehcet SyndromeFemaleHLA-B51 AntigenHumansInfliximabPrednisoneQuality of LifeTreatment OutcomeAntibodies, MonoclonalHLA-B51 AntigenInfliximabPrednisoneBehçet’s diseaseGlucocorticoidsInfliximabNeurologic and ocular involvement

Identifiers

PMID29777341
OpenAlexW2803648300

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.